News

Widely-available Drug May Benefit Glioblastoma Treatment Based on data from NBTS’s Defeat GBM Research Collaborative and with support from the Sharpe family, Dr. Paul Mischel (Stanford University) and his team found that the antidepressant drug, fluoxetine (common brand name: Prozac), targets tumor metabolism and inhibits epidermal growth factor (EGFR) signaling, triggering the killing of glioblastoma (GBM) cells in laboratory models. Dr. […] December 17, 2021

Years of Scientific Progress Lead to Hope for Glioblastoma Patient With funding from the National Brain Tumor Society, Clark C. Chen, MD, PhD of the University of Minnesota is ready to start a clinical trial for a drug that is already showing early promise for a glioblastoma patient. The following blog, which has been lightly edited, was originally published on the University of Minnesota’s Neurosurgery […] November 4, 2021

NBTS Brain Tumor Clinical Trials Report: Q2 2021 It can be hard to keep track of new clinical trial opportunities opening across the United States, especially as we continue to navigate the public health crisis created by the coronavirus (COVID-19). There are many clinical trials actively enrolling patients, and this report provides a summary of the studies that have recently opened or started […] June 30, 2021

Innovating Brain Tumor Clinical Trials: Lessons Learned During the COVID-19 Experience The global COVID-19 pandemic disrupted nearly every facet of life in 2020, and brain cancer research, particularly clinical trials, was not spared from its impacts. As is often the case, though, with disruption comes the opportunity to innovate. Convening key stakeholders across the brain tumor community, the National Brain Tumor Society (NBTS) has taken stock […] May 7, 2021

NBTS Brain Tumor Clinical Trials Report: Q1 2021 It can be hard to keep track of new clinical trial opportunities opening across the United States, especially during the current public health crisis created by the coronavirus (COVID-19). However, there are many clinical trials still actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for […] April 8, 2021